HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.
Showing posts with label Value in Health. Show all posts
Showing posts with label Value in Health. Show all posts

Wednesday, 24 March 2021

Valuing the care in healthcare: priorities and trade-offs - Honorary Professor of Clinical Decision Science writes for the Journal of Medical Ethics

Healthcare decisions are complex, whether we are considering individual choices about our own health, or policy decisions made by political or professional bodies.  Disease and the actions taken to prevent, diagnose and treat it, may have widespread ramifications on all aspects of our lives.  Furthermore, policy and personal decisions in other aspects of our life, may have significant individual or public health implications.  These effects have been starkly highlighted by the current pandemic, where we have seen the widespread effects of disease and its management, not only on health outcomes, but on the economy, employment and personal freedoms.

Image of Jonathan Michaels
Jonathan Michaels
Politicians have told us that they are “following the science”, but it is clear from the diversity of responses that they are making different trade-offs, which may reflect divergent ethical and philosophical responses to the situation.

About a year ago, I wrote a paper on the potential for epistemic injustices in evidence-based healthcare policy, that highlighted some of the potential issues, biases and distortions that may undermine the legitimacy of evidence-based decisions.  However, this is only half the story.  Even with the best evidence to predict the consequences of our decisions, we are still faced with value judgements about the trade-offs between different processes and outcomes.  My current paper was written at about the same time, before the pandemic hit, and addresses some of these value judgments.  If I was writing it today, I would have many examples from the different approaches to the health and economic challenges that the pandemic presents.

In their responses to the pandemic, we have heard politicians variously describing saving lives, preserving jobs, reopening schools or other activities as their ‘top priority’.  Priority is a comparative term, but we rarely hear that such-and-such is a priority over x, y or z.  It is easy enough to state that all sorts of things are top priorities if we are not asked to specify what they are being prioritised over.  If everything is prioritised, then nothing is a priority.

In practice, we constantly make trade-offs between the many aspects of our life that we value, whether this is accepting the risks of a surgical procedure to relieve the pain of arthritis, or accepting the risks of car travel, to preserve our freedom of movement.  In time, we may learn to live with the pandemic as we do with flu, admitting that there is a level of mortality that is an acceptable trade-off against our personal freedoms, our social life and the health of the economy.  We may each have a different perspective on such trade-offs.  The debate over the timing of second vaccine doses highlights such differences.  A public health approach may find that the greater good is served by using limited vaccine supplies to provide single doses to a greater number, delaying the second dose, while doctors with individual patient’s interests at heart, may call for the shorter delay, evaluated in trials.

We value many aspects of our life that may be affected by healthcare decisions.  In making decisions we must decide whose values and preferences are relevant and how these should be elicited and incorporated.  Those making policy decisions in healthcare have widely adopted the quality adjusted life year (QALY) as a metric that combines the various dimensions of health with the length of survival.  However, this does not capture all the relevant aspects of health outcomes, let alone all the other effects that might be relevant to such decisions.  A number of ‘value assessment frameworks’ have been suggested that incorporate other potential consequences of disease, disability and healthcare in the decision-making process.

In this paper, I argue that such frameworks may privilege the interests of certain commercial or political interests that influence their development and adoption.  The identified elements of value tend to be those that favour new, high cost, drugs and technologies, and many run the risk of double counting or inflating the apparent value of certain technologies.  This is likely to result in decisions that fail to incorporate other features of healthcare that are highly valued by society, particularly those relating to care processes.  Valued aspects that are most likely to be displaced are those such as dignity, compassion, choice and autonomy, all of which may have significant resource implications but are more difficult to quantify.

If we are to develop healthcare policy that reflects societal values and achieves distributive justice, then more attention is required to identify all the aspects of healthcare that we value and ensure that we do not produce procedural mechanisms that result in their displacement by costly new technologies.

 Paper title: Value assessment frameworks: who is valuing the care in healthcare?

Author: Jonathan Michaels

Affiliations: School of Health and Related Research, University of Sheffield

Competing interests: None

Social media accounts of post author(s): @JonM_ScHARR

The original blog post appeared in the Journal of Medical Ethics and is republished under a CC-BY-NC licence https://blogs.bmj.com/medical-ethics/2021/03/16/valuing-the-care-in-healthcare-priorities-and-trade-offs/

Monday, 3 June 2019

New Paper - Cost-effectiveness of docetaxel and paclitaxel for adjuvant treatment of early breast cancer in South Africa based on model adaptation

Image of Abualbishr Alshreef
Abualbishr Alshreef

HEDS Research Fellow Abualbishr Alshreef has led on a research collaboration on assessing the appropriateness of model adaptation methods to the context of low and middle-income countries. The research is a collaboration between the University of Sheffield, University of Leeds, University of York, Imperial College London, University of the Witwatersrand and National Department of Health (South Africa). 

Findings from the case study on the cost-effectiveness of docetaxel and paclitaxel-containing chemotherapy regimens based on model adaptation from UK to South Africa is published in Value in Health Regional Issues. The study represents an independent research funded by the White Rose Collaboration Fund.

The study found that “docetaxel and paclitaxel are predicted to be cost-effective as adjuvant treatment for early breast cancer in South Africa”.

The study highlighted that “model adaptation from high-income countries to middle-income countries contexts is possible but not easy and may need considerable resources”. HEDS contributions to this paper are from Abualbishr Alshreef, Sue Ward and Simon Dixon.
For the full paper, please click here https://authors.elsevier.com/sd/article/S2212109919300470 

Tuesday, 21 May 2019

Dr Monica Hernandez has won the 2019 ISPOR Value in Health paper of the year award

Image of Dr Mónica Hernández Alava
Dr Mónica Hernández 
Alava
We are proud to announce that HEDS Reader in Econometrics Dr 
Mónica Hernández Alava has won the 2019 ISPOR Value in Health paper of the year award. This is for the paper, “EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom,” Value in Health 2018;21(1):49-56.

This paper includes Dr Hernández is the lead author alongside Professor Steve Pudney and Professor Allan Wailoo from ScHARR plus collaborators from several other universities. It is the result of work Monica led as part of an MRC Methodology grant on mapping, and the NICE Decision Support Unit. 

The paper is a great example of collaborative work building on her recent research in the area of modelling health state utility data. The paper combines cutting edge methods developed for mapping health utility data, demonstration of the impact in real-life cost-effectiveness studies, and addresses a critical policy question for decision makers like the National Institute of Health and Care Excellence (NICE), who part-funded the work through their Decision Support Unit where Monica is a member.    

https://www.ispor.org/about/awards-grants/scientific-achievement-and-leadership-awards/value-in-health-paper-of-the-year-award  

Wednesday, 1 May 2019

Global Expert Panel Publishes New Recommendations on the Use of Health State Utilities in Cost-Effectiveness Models


Image of Value in Health Journal
ISPOR Value in Health
Global Expert Panel Publishes New Recommendations on the 

Use of Health State Utilities in Cost-Effectiveness Models  

A Report of the ISPOR Good Practices for Outcomes Research Task Force 

Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of new recommendations from the Health State Utilities in Cost-Effectiveness Models ISPOR Good Practices for Outcomes Research Task Force. The report, “Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report,” was published in the March 2019 issue of Value in Health. 

The task force report provides recommendations for researchers who identify, review, and synthesize health state utilities (HSUs) for use in cost-effectiveness models; analysts who use the results in models; and reviewers who critically appraise the suitability and validity of the HSUs selected for use in models. The report provides guidance regarding:
  1. The iterative nature of searching for HSUs, reviewing and synthesizing the evidence identified and their application in cost-effectiveness models 
  2. Minimum reporting standards for HSUs used in cost-effectiveness models
  3. Use of HSUs in cost-effectiveness models

The task force report’s internationally applicable SpRUCE checklist should be used by reviewers of manuscripts and reports of modelling work to ensure the suitability, validity, and quality of the HSUs are sufficient to inform healthcare policy making.   
Image of Professor John Brazier
Professor John Brazier

“This report provides guidance for identifying, reviewing, and synthesizing health state utilities from the literature and using health state utilities in cost-effectiveness models,” said author John Brazier, PhD, Dean and Professor of Health Economics, School of Health and Related Research, University of Sheffield, Sheffield, England, UK. 

“This task force report was written to correct current poor practice in health state utility identification. Analysts frequently cite dated values used in previous cost-effectiveness models without undertaking basic quality checks of the data in the original source material, such as the relevance of the patient population, utility instrument, elicitation method or sources of the preference weights. These shortcuts can render the results uninterpretable when health state utilities derived from a variety of methods and populations are pieced together.” These task force recommendations and the ISPOR SpRUCE checklist offer a structured and more transparent basis for identifying and reporting the HSUs used in a cost-effectiveness model.”

The Importance of Health State Utilities:
Health state utilities, which estimate the value of a health state on a scale where 1 represents full health and 0 represents dead, are used to inform policy decisions in many parts of the world. Preference value estimates are usually obtained by querying a sample of the general population or a patient population. If HSUs are not available from clinical trial data and conducting a study to collect this evidence is not feasible, HSUs are often obtained from the literature. This approach can be problematic because analysts frequently cite outdated evidence used in previous evaluations, systematic reviews of the literature are rarely undertaken for HSUs, and current reporting standards of HSUs used in cost-effectiveness models are often poor.



ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.

ABOUT VALUE IN HEALTH
Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2017 impact factor score is 5.494. Value in Health is ranked 3rd among 94 journals in healthcare sciences and services, 3rd among 79 journals in health policy and services, and 6th among 353 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
Web: www.ispor.org/valueinhealth | Twitter: www.twitter.com/isporjournals (@ISPORjournals)

ABOUT ISPOR GOOD PRACTICES FOR OUTCOMES RESEARCH TASK FORCE REPORTS
ISPOR has earned an international reputation for research excellence based, in part, on its Good Practices for Outcomes Research Task Force Reports. These highly cited reports are expert consensus recommendations on good practice standards for outcomes research (clinical, economic, and patient-reported outcomes) and on the use of this research in healthcare decision making. ISPOR Task Forces comprise subject matter experts representing different stakeholders from diverse work environments (ie, regulators, payers, manufacturers, technology assessors, etc from research, government, academic, and industry sectors around the world). All ISPOR Good Practices for Outcomes Research Reports are published in the Society’s scientific journal, Value in Health, and are made freely available as part of the Society’s mission. The Society’s Good Practices for Outcomes Research Reports have been recognized with an ASAE “Power of A” award that acknowledges innovative, effective, and broad-reaching programs that have a positive impact on the world.

Thursday, 21 February 2019

Join us for our FREE Measuring and Valuing Health online course - MOOC - 4th March

HEDS are running their popular Measuring and Valuing Health online course - MOOC on Measuring and Valuing Health through the FutureLearn platform from the 4th of March.

Learn how Patient Reported Outcome Measures and Quality Adjusted Life Years can compare treatments and inform healthcare spending.

Sign up here


Image of FutureLearn course page
FutureLearn course page
How do we decide which drugs and treatments to fund?
Healthcare systems around the world are increasingly under pressure to fund drugs, treatments and other healthcare interventions.
On this course, you’ll learn how health outcome measures can help us to make more informed decisions about where to spend our limited healthcare budgets.
You can continue to learn about healthcare decision-making with our next course Health Technology Assessment (HTA): Choosing Which Treatments Get Funded.
What topics will we cover?

The course focuses on two different types of measures, asking how they’re developed and calculated, and how they’re used by decision makers in practice:

Patient Reported Outcome Measures (PROMs): which are measures completed by the patients themselves, about their health, symptoms, functioning, well-being or satisfaction with treatment.

Quality Adjusted Life Years (QALYs): which compare the benefits of different treatment options, based on the quality and quantity of life they yield.

By the end of the course, you'll be able to...

Discuss what health means and how to measure its impact on quality of life.

Evaluate how to develop and use patient reported outcome measures including their limitations in decision-making.

Calculate QALYs in simple examples to arrive at values which can be used to compare treatment benefits.

Perform a time trade off to develop an understanding of how this method can be used to value health states and generate preference weights.

Debate who should value our health. Should it be patients, health professionals or the general public and should this be different for children’s health?

Compare where QALYs are used in healthcare decision-making worldwide and discuss the merits of this method compared to those used where you live.


Who is the course for?

This course will help you understand how and why choices about drugs and treatments have been made. It may inspire you to think about a career in healthcare, local decision making or academia.

You may even wish to take your learning further, with the University of Sheffield’s Masters degrees and short courses in areas such as health economics, public health and international healthcare technology assessment.

You can find out more about this subject in Dr Katherine Stevens’ post for the FutureLearn blog: “How do we make decisions in healthcare about which drugs and treatments to fund?”

What do people say about this course?

"Thank you for a very well structured and presented course. The interactive elements (trying out the measures and voting) helped me think and engage more. This is a great introduction to a complex subject and has motivated me to find out more."

Gill Charman


Course leaders.

Thursday, 26 July 2018

Measuring and Valuing Health MOOC from HEDS

The Measuring and Valuing Health MOOC developed by HEDS is currently running on the FutureLearn website. The course runs for three weeks and takes three hours per week to study. Learn how Patient Reported Outcome Measures and Quality Adjusted Life Years can compare treatments and inform healthcare spending. Healthcare systems around the world are increasingly under pressure to fund drugs, treatments and other healthcare interventions.
On this course, you’ll learn how health outcome measures can help us to make more informed decisions about where to spend our limited healthcare budgets.
You can continue to learn about healthcare decision-making with our next course Health Technology Assessment (HTA): Choosing Which Treatments Get Funded.
Image of FutureLearn course page
Future Learn 
What topics will you cover?
The course focuses on two different types of measures, asking how they’re developed and calculated, and how they’re used by decision makers in practice:

Patient Reported Outcome Measures (PROMs): which are measures completed by the patients themselves, about their health, symptoms, functioning, well-being or satisfaction with treatment.

Quality Adjusted Life Years (QALYs): which compare the benefits of different treatment options, based on the quality and quantity of life they yield.


Who is the course for?
This course will help you understand how and why choices about drugs and treatments have been made. It may inspire you to think about a career in healthcare, local decision making or academia.
You may even wish to take your learning further, with the University of Sheffield’s Masters degrees and short courses in areas such as health economics, public health and international healthcare technology assessment.
You can find out more about this subject in Dr Katherine Stevens’ post for the FutureLearn blog: “How do we make decisions in healthcare about which drugs and treatments to fund?”
What will you achieve?
By the end of the course, you'll be able to...
  • Discuss what health means and how to measure its impact on quality of life.
  • Evaluate how to develop and use patient reported outcome measures including their limitations in decision-making.
  • Calculate QALYs in simple examples to arrive at values which can be used to compare treatment benefits.
  • Perform a time trade off to develop an understanding of how this method can be used to value health states and generate preference weights.
  • Debate who should value our health. Should it be patients, health professionals or the general public and should this be different for children’s health?
  • Compare where QALYs are used in healthcare decision-making worldwide and discuss the merits of this method compared to those used where you live.